243 related articles for article (PubMed ID: 30111438)
21. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma cells' capacity to decompose H
Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
[TBL] [Abstract][Full Text] [Related]
23. Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function.
Zhou L; Yu W; Jayabalan DS; Niesvizky R; Jaffrey SR; Huang X; Xu G
Front Cell Dev Biol; 2020; 8():605989. PubMed ID: 33392195
[TBL] [Abstract][Full Text] [Related]
24. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
25. CRISPRing the CRL4
Neri P
Blood; 2018 Sep; 132(12):1219-1220. PubMed ID: 30237253
[No Abstract] [Full Text] [Related]
26. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
[TBL] [Abstract][Full Text] [Related]
27. New mechanism of lenalidomide activity.
Keevan J; Figg WD
Cancer Biol Ther; 2014 Aug; 15(8):968-9. PubMed ID: 24840055
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Guirguis AA; Ebert BL
Curr Opin Cell Biol; 2015 Dec; 37():61-7. PubMed ID: 26512454
[TBL] [Abstract][Full Text] [Related]
29. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
30. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
[TBL] [Abstract][Full Text] [Related]
31. Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.
Del Prete D; Rice RC; Rajadhyaksha AM; D'Adamio L
J Biol Chem; 2016 Aug; 291(33):17209-27. PubMed ID: 27325702
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
[TBL] [Abstract][Full Text] [Related]
33. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
[TBL] [Abstract][Full Text] [Related]
34. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
36. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
38. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
[TBL] [Abstract][Full Text] [Related]
39.
Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
[TBL] [Abstract][Full Text] [Related]
40. What is the functional role of the thalidomide binding protein cereblon?
Chang XB; Stewart AK
Int J Biochem Mol Biol; 2011; 2(3):287-94. PubMed ID: 22003441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
